ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Exploring the antibacterial and antibiofilm potential of 1,8-cineole against Escherichia coli through in vitro, gene expression, and in silico analyses.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing uropathogenic Escherichia coli (UPEC), particularly strains with multidrug resistance (MDR) and enhanced biofilm-forming capacity, represents a major challenge in the management of urinary tract infections. This study investigated the antibacterial, antibiofilm, and mechanistic effects of 1,8-cineole against MDR ESBL-producing UPEC isolates. Antibacterial activity was evaluated using disk diffusion and minimum inhibitory concentration (MIC) assays. Membrane integrity, antibiofilm activity, and structural alterations were assessed through intracellular protein and nucleic acid leakage analyses, biofilm eradication assays, and scanning electron microscopy (SEM), respectively. Quantitative real-time PCR (qRT-PCR) was used to analyze the expression of biofilm-associated genes. Molecular docking was performed to investigate interactions between 1,8-cineole and major UPEC biofilm-related proteins. 1,8-Cineole exhibited marked antibacterial activity against MDR ESBL-producing UPEC isolates, with inhibition zone diameters of 13.4 ± 1.7 mm and MIC values of 1.4 to 2.8 mg/mL. Treatment induced significant leakage of intracellular proteins and nucleic acids, indicating disruption of membrane integrity. Exposure to 4 × MIC markedly impaired mature biofilm architecture. SEM analysis confirmed severe morphological damage, including membrane disruption and cellular deformation. qRT-PCR analysis demonstrated significant downregulation of the biofilm-associated genes csgA, csgD, fimH, luxS, and pgaC following treatment with 1,8-cineole. Molecular docking further revealed stable interactions between 1,8-cineole and key biofilm regulatory proteins, particularly with FimH. 1,8-Cineole exerts potent antibacterial and antibiofilm activity against MDR ESBL-producing UPEC through membrane destabilization and modulation of biofilm-associated pathways, supporting its potential as a plant-derived antimicrobial candidate for biofilm-associated urinary tract infections.
Indexed as
Identifiers
42547589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.